MetLife Inc. (US59156R1086) stock remains steady around $96.66 after reporting strong Q2 2026 earnings, with adjusted EPS of $2.43 beating consensus estimates of $2.30 and revenue reaching $19.15 billion. The company has delivered two consecutive quarters of EPS beats, and analysts expect continued earnings growth, with a Q3 2026 EPS consensus of $2.55 and full-year EPS of $9.30. The stock currently trades with a market capitalization of $62.21 billion and offers a dividend yield of 2.37%, with institutional investors holding a significant 94.99% stake.

Pfizer CEO Albert Bourla recently purchased $1 million worth of company stock, acquiring 38,000 shares at $26.34 each. This insider buying signals confidence in Pfizer's future, particularly as the company aims to convince investors about improving operational trends and its medication pipeline. While the purchase itself won't significantly alter Pfizer's outlook, it sends a strong message about the CEO's belief in the company's potential for sustained earnings growth.

BTIG Research has reiterated its "Buy" rating for BrightSpring Health Services (NASDAQ:BTSG), setting a $90 price target, which suggests a potential upside of 50.8% from its current share price. This aligns with a broader analyst consensus of "Buy" and an average target price of $70.71. The company recently exceeded Q2 earnings expectations, reporting $0.45 EPS against a $0.40 estimate and revenue of $3.87 billion, up 23% year-over-year.

Northcoast Research upgraded CAVA Group (NYSE:CAVA) from "sell" to "neutral," despite ongoing profitability concerns and insider stock sales. The company recently reported better-than-expected quarterly earnings and revenue, with strong sales growth and increased traffic. However, higher operational costs and lingering food-safety fears remain factors influencing its valuation and analyst outlooks.

Piper Sandler has reiterated its "Overweight" rating for Trimble (NASDAQ:TRMB) and set an $87 price target, suggesting a 54% upside. This comes after Trimble reported strong Q2 earnings, beating revenue and EPS expectations, and raising its fiscal 2026 EPS guidance, despite a significant goodwill impairment charge. The company's stock currently holds a "Moderate Buy" consensus rating among analysts.

Candel Therapeutics reported a net loss of $38.9 million for Q2 2026, with $201.6 million in cash and equivalents, expected to fund operations into Q1 2028. The company plans to submit a Biologics License Application for aglatimagene in prostate cancer in Q4 2026, highlighting progress in its clinical programs and commercial readiness. Key financial figures include increased R&D and G&A expenses, and significant clinical milestones for aglatimagene in prostate cancer and NSCLC.

Fitch Ratings has downgraded Baidu, Inc.'s long-term issuer default rating to A- from A, citing a structural decline in the company’s search advertising business and lower EBITDA generation. The downgrade is attributed to intensifying competition from AI chatbots and other platforms, which are eroding monetization in Baidu's legacy search business. Despite expectations for AI Cloud Infrastructure revenue growth, Fitch projects relatively high gross leverage due to lower EBITDA before a gradual recovery.

This article announces that Candel Therapeutics Inc. filed a Form 8K on August 13th, as reported by Investing.com. The brief piece includes the company's stock symbol CADL and its performance for the day. No further details about the Form 8K content are provided within the article.

Kimco Realty's stock increased following a 12% dividend hike to $0.28 per share and the issuance of $600 million in exchangeable senior notes due in 2031. The company's shares closed at $24.15, reflecting investor confidence in its cash-return strength and balance-sheet management. This positive market reaction is further supported by strong Q2 results, including 4.0% year-over-year revenue growth and a record 96.4% occupancy rate for its grocery-anchored shopping centers.

PTC has launched the FeatureScript MCP Server in its Onshape CAD and PDM platform, allowing engineers to create custom CAD features using natural language and AI, eliminating the need for programming experience. This new capability automates feature development, testing, and debugging, enabling companies to capture and scale engineering knowledge by transforming design practices into reusable tools. PTC emphasizes that this innovation focuses on creating lasting engineering capabilities rather than just generating CAD models, aligning with its vision for an Intelligent Product Lifecycle.